Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Cited by (1,051)

Items 201–300 of 1,051

1. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
   Coelho, Matthew A., de Carné Trécesson, Sophie, Rana, Sareena, Zecchin, Davide, Moore, Christopher, Molina-Arcas, Miriam, East, Philip, Spencer-Dene, Bradley, Nye, Emma, Barnouin, Karin et al. · 2017 · Immunity
2. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
   Derosa, Lisa, Routy, Bertrand, Thomas, Andrew Maltez, Iebba, Valerio, Zalcman, Gerard, Friard, Sylvie, Mazieres, Julien, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Goldwasser, François et al. · 2022 · Nature Medicine
3. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
   Antonio Passaro, Maise Al Bakir, Emily G. Hamilton, Maximilian Diehn, Fabrice André, Sinchita Roy‐Chowdhuri, Giannis Mountzios, Ignacio Ivan Wistuba, Charles Swanton, Solange Peters · 2024 · Cell
4. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
   Zhao, Pengfei, Li, Li, Jiang, Xiaoyue, Li, Qin · 2019 · Journal of Hematology & Oncology
5. Mechanisms and therapeutic implications of hypermutation in gliomas
   Mehdi Touat, Yvonne Y. Li, Adam N. Boynton, Liam Flinn Spurr, Julian Bryan Iorgulescu, Craig L. Bohrson, Isidro Cortés‐Ciriano, Cristina Birzu, Jack E. Geduldig, Kristine Pelton et al. · 2020 · Nature
6. Challenges and Opportunities for Pancreatic Cancer Immunotherapy
   Bear, Adham S., Vonderheide, Robert H., O'Hara, Mark H. · 2020 · Cancer Cell
7. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
   Jordan, Emmet J., Kim, Hyunjae R., Arcila, Maria E., Barron, David, Chakravarty, Debyani, Gao, JianJiong, Chang, Matthew T., Ni, Andy, Kundra, Ritika, Jonsson, Philip et al. · 2017 · Cancer Discovery
8. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
   Zhu, Andrew X., Abbas, Alexander R., de Galarreta, Marina Ruiz, Guan, Yinghui, Lu, Shan, Koeppen, Hartmut, Zhang, Wenjun, Hsu, Chih-Hung, He, Aiwu Ruth, Ryoo, Baek-Yeol et al. · 2022 · Nature Medicine
9. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
   Arlauckas, Sean P., Garris, Christopher S., Kohler, Rainer H., Kitaoka, Maya, Cuccarese, Michael F., Yang, Katherine S., Miller, Miles A., Carlson, Jonathan C., Freeman, Gordon J., Anthony, Robert M. et al. · 2017 · Science Translational Medicine
10. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome
    Wolf H. Fridman, Maxime Meylan, Florent Petitprez, Cheng‐Ming Sun, Antoîne Italiano, Catherine Sautès‐Fridman · 2022 · Nature Reviews Clinical Oncology
11. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
    Deborah B. Doroshow, Miguel F. Sanmamed, Katherine Hastings, Katerina A. Politi, David L. Rimm, Lieping Chen, Ignacio Melero, Kurt Alex Schalper, Roy S. Herbst · 2019 · Clinical Cancer Research
12. Pan-cancer integrative histology-genomic analysis via multimodal deep learning
    Chen, Richard J., Lu, Ming Y., Williamson, Drew F.K., Chen, Tiffany Y., Lipkova, Jana, Noor, Zahra, Shaban, Muhammad, Shady, Maha, Williams, Mane, Joo, Bumjin et al. · 2022 · Cancer Cell
13. A molecular portrait of microsatellite instability across multiple cancers
    Isidro Cortés‐Ciriano, Sejoon Lee, Woong‐Yang Park, Tae‐Min Kim, Peter J. Park · 2017 · Nature Communications
14. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
    Charlene Marie Fares, Eliezer M. Van Allen, Charles G. Drake, James Patrick Allison, Siwen Hu‐Lieskovan · 2019 · American Society of Clinical Oncology Educational Book
15. A neoantigen fitness model predicts tumor response to checkpoint blockade immunotherapy
    M. Łuksza, N. Riaz, V. Makarov, V. Balachandran, M. Hellmann, A. Solovyov, N. Rizvi, T. Merghoub, A. Levine, T. Chan et al. · 2017 · Nature
16. DNA Damage and Repair Biomarkers of Immunotherapy Response
    Kent William Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, Alan D. D’Andrea · 2017 · Cancer Discovery
17. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
    Kim, J.M., Chen, D.S. · 2016 · Annals of Oncology
18. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
    Yongshuai Jiang, Ming Chen, Hong Nie, Yuanyang Yuan · 2019 · Human Vaccines & Immunotherapeutics
19. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
    Sonja Kleffel, Christian Posch, Steven R. Barthel, Hansgeorg Mueller, Christoph Schlapbach, Emmanuella Guenova, Christopher P. Elco, Nayoung Lee, Vikram R. Juneja, Qian Zhan et al. · 2015 · Cell
20. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment
    Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Aref, Amir R., Skoulidis, Ferdinandos, Herter-Sprie, Grit S., Buczkowski, Kevin A., Liu, Yan, Awad, Mark M., Denning, Warren L. et al. · 2016 · Cancer Research
21. Evolving synergistic combinations of targeted immunotherapies to combat cancer
    Ignacio Melero, David M. Berman, Maria Angela Aznar, Alan J. Korman, José Luis Perez‐Gracia, John B.A.G. Haanen · 2015 · Nature reviews. Cancer
22. Cancer immunotherapies targeting the PD-1 signaling pathway
    Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, Tasuku Honjo · 2017 · Journal of Biomedical Science
23. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
    Giovanni Germano, Simona Lamba, Giuseppe Rospo, Ludovic Barault, Alessandro Magrì, Federica Maione, Mariangela Russo, Giovanni Crisafulli, Alice Bartolini, Giulia Lerda et al. · 2017 · Nature
24. The emerging clinical relevance of genomics in cancer medicine
    Michael F. Berger, Elaine R. Mardis · 2018 · Nature Reviews Clinical Oncology
25. Classification of triple-negative breast cancers based on Immunogenomic profiling
    Yin He, Zehang Jiang, Cai Chen, Xiaosheng Wang · 2018 · Journal of Experimental & Clinical Cancer Research
26. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
    Rizvi, Naiyer A., Cho, Byoung Chul, Reinmuth, Niels, Lee, Ki Hyeong, Luft, Alexander, Ahn, Myung-Ju, van den Heuvel, Michel M., Cobo, Manuel, Vicente, David, Smolin, Alexey et al. · 2020 · JAMA Oncology
27. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
    Miao, Diana, Margolis, Claire A., Vokes, Natalie I., Liu, David, Taylor-Weiner, Amaro, Wankowicz, Stephanie M., Adeegbe, Dennis, Keliher, Daniel, Schilling, Bastian, Tracy, Adam et al. · 2018 · Nature Genetics
28. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
    Harding, James J., Nandakumar, Subhiksha, Armenia, Joshua, Khalil, Danny N., Albano, Melanie, Ly, Michele, Shia, Jinru, Hechtman, Jaclyn F., Kundra, Ritika, El Dika, Imane et al. · 2019 · Clinical Cancer Research
29. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
    Steve Lu, Julie E. Stein, David L. Rimm, Daphne W. Wang, Michael A. Bell, Douglas Buckner Johnson, Jeffrey Alan Sosman, Kurt Alex Schalper, Robert A. Anders, Hao Wang et al. · 2019 · JAMA Oncology
30. Tumor neoantigens: building a framework for personalized cancer immunotherapy
    Matthew M. Gubin, Maxim N. Artyomov, Elaine R. Mardis, Robert D. Schreiber · 2015 · Journal of Clinical Investigation
31. T cell receptor (TCR) signaling in health and disease
    Kinjal Shah, Amr A. Al-Haidari, Jianmin Sun, Julhash Uddin Kazi · 2021 · Signal Transduction and Targeted Therapy
32. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers
    Ready, Neal, Hellmann, Matthew D., Awad, Mark M., Otterson, Gregory A., Gutierrez, Martin, Gainor, Justin F., Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela et al. · 2019 · Journal of Clinical Oncology
33. Driving CAR T-cells forward
    Jackson, Hollie J., Rafiq, Sarwish, Brentjens, Renier J. · 2016 · Nature Reviews Clinical Oncology
34. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
    Tianyu Tang, Xing Huang, Gang Zhang, Zhengtao Hong, Xueli Bai, Tingbo Liang · 2021 · Signal Transduction and Targeted Therapy
35. Role of Immunotherapy in Triple-Negative Breast Cancer
    Tanya Elizabeth Keenan, Sara M. Tolaney · 2020 · Journal of the National Comprehensive Cancer Network
36. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
    Florent Petitprez, Maxime Meylan, Aurélien de Reyniès, Catherine Sautès‐Fridman, Wolf H. Fridman · 2020 · Frontiers in Immunology
37. The hallmarks of successful anticancer immunotherapy
    Galluzzi, Lorenzo, Chan, Timothy A., Kroemer, Guido, Wolchok, Jedd D., López-Soto, Alejandro · 2018 · Science Translational Medicine
38. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
    Rodig, Scott J., Gusenleitner, Daniel, Jackson, Donald G., Gjini, Evisa, Giobbie-Hurder, Anita, Jin, Chelsea, Chang, Han, Lovitch, Scott B., Horak, Christine, Weber, Jeffrey S. et al. · 2018 · Science Translational Medicine
39. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis
    Lee, Chee Khoon, Man, Johnathan, Lord, Sally, Cooper, Wendy, Links, Matthew, Gebski, Val, Herbst, Roy S., Gralla, Richard J., Mok, Tony, Yang, James Chih-Hsin · 2018 · JAMA Oncology
40. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
    Grosser, Rachel, Cherkassky, Leonid, Chintala, Navin, Adusumilli, Prasad S. · 2019 · Cancer Cell
41. Molecular and histological correlations in liver cancer
    Julien Caldéraro, Marianne Ziol, Valérie Paradis, Jessica Zucman‐Rossi · 2019 · Journal of Hepatology
42. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC
    Jin, Yueping, Dong, Hui, Xia, Liliang, Yang, Yi, Zhu, Yongqiang, Shen, Yan, Zheng, Huajun, Yao, Chengcheng, Wang, Ying, Lu, Shun · 2019 · Journal of Thoracic Oncology
43. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
    Max D. Wellenstein, Karin E. de Visser · 2018 · Immunity
44. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
    Weide, Benjamin, Martens, Alexander, Hassel, Jessica C., Berking, Carola, Postow, Michael A., Bisschop, Kees, Simeone, Ester, Mangana, Johanna, Schilling, Bastian, Di Giacomo, Anna Maria et al. · 2016 · Clinical Cancer Research
45. Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
    Apolo, Andrea B., Infante, Jeffrey R., Balmanoukian, Ani, Patel, Manish R., Wang, Ding, Kelly, Karen, Mega, Anthony E., Britten, Carolyn D., Ravaud, Alain, Mita, Alain C. et al. · 2017 · Journal of Clinical Oncology
46. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
    Leigh Jessica Marcus, Lola A. Fashoyin‐Aje, Martha Boeri Donoghue, Mengdie Yuan, Lisa Rodríguez, Pamela S. Gallagher, Reena Philip, Soma Ghosh, Marc Robert Theoret, Julia A. Beaver et al. · 2021 · Clinical Cancer Research
47. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
    Lisberg, A., Cummings, A., Goldman, J.W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J. et al. · 2018 · Journal of Thoracic Oncology
48. Cancer Neoantigens
    Ton N. Schumacher, Wouter Scheper, Pia Kvistborg · 2018 · Annual Review of Immunology
49. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
    Benci, Joseph L., Johnson, Lexus R., Choa, Ruth, Xu, Yuanming, Qiu, Jingya, Zhou, Zilu, Xu, Bihui, Ye, Darwin, Nathanson, Katherine L., June, Carl H. et al. · 2019 · Cell
50. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
    Wouter Scheper, Sander Kelderman, Lorenzo F. Fanchi, Carsten Linnemann, Gavin M. Bendle, Marije A. J. de Rooij, Christian Hirt, Riccardo Mezzadra, Maarten Slagter, Krijn Kristian Dijkstra et al. · 2018 · Nature Medicine
51. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
    Shetal Arvind Patel, Andy J. Minn · 2018 · Immunity
52. The hallmarks of cancer immune evasion
    Claudia Galassi, Timothy An-thy Chan, Ilio Vitale, Lorenzo Galluzzi · 2024 · Cancer Cell
53. Resistance to PD1/PDL1 checkpoint inhibition
    Jake S. O’Donnell, Georgina Venetia Long, Richard A. Scolyer, Michele W.L. Teng, Mark John Smyth · 2016 · Cancer Treatment Reviews
54. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
    Douglas Buckner Johnson, Monica Valeria Estrada, Roberto Salgado, Violeta M. Sanchez, Deon Bryant Doxie, Susan R. Opalenik, Anna E. Vilgelm, Emily Feld, Adam S. Johnson, Allison R. Greenplate et al. · 2016 · Nature Communications
55. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
    Tang Qing, Yun Chen, Xiaojuan Li, Shunqin Long, Yao Shi, Yaya Yu, Wanyin Wu, Ling Han, Sumei Wang · 2022 · Frontiers in Immunology
56. Genetic Mechanisms of Immune Evasion in Colorectal Cancer
    Grasso, Catherine S., Giannakis, Marios, Wells, Daniel K., Hamada, Tsuyoshi, Mu, Xinmeng Jasmine, Quist, Michael, Nowak, Jonathan A., Nishihara, Reiko, Qian, Zhi Rong, Inamura, Kentaro et al. · 2018 · Cancer Discovery
57. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
    Stefano Trebeschi, Silvia Girolama Drago, Nicolai J. Birkbak, Ieva Kurilova, Adriana Calin, Andrea Delli Pizzi, Ferry Lalezari, Doenja M. J. Lambregts, Maartje W. Rohaan, Chintan Parmar et al. · 2019 · Annals of Oncology
58. The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
    Hanke L. Matlung, Katka Szilagyi, Neil Barclay, Timo K. van den Berg · 2017 · Immunological Reviews
59. Advances in cancer immunotherapy 2019 – latest trends
    Stephan Krüger, Matthias Ilmer, Sebastian Kobold, Bruno Loureiro Cadilha, Stefan Endres, Steffen Ormanns, Gesa Schuebbe, Bernhard Willibald Renz, Jan Goesta D’Haese, Hans Schlößer et al. · 2019 · Journal of Experimental & Clinical Cancer Research
60. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers
    Teo, Min Yuen, Seier, Kenneth, Ostrovnaya, Irina, Regazzi, Ashley M., Kania, Brooke E., Moran, Meredith M., Cipolla, Catharine K., Bluth, Mark J., Chaim, Joshua, Al-Ahmadie, Hikmat et al. · 2018 · Journal of Clinical Oncology
61. PD-1/PD-L1 inhibitors
    Joel Chaim Sunshine, Janis Marie Taube · 2015 · Current Opinion in Pharmacology
62. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
    Paul C. Tumeh, Matthew David Hellmann, Omid Hamid, Katy K. Tsai, Kimberly Leticia Loo, Matthew A. Gubens, Michael D. Rosenblum, Christina L. Harview, Janis Marie Taube, Nathan R. Handley et al. · 2017 · Cancer Immunology Research
63. DNA mismatch repair in cancer
    Marina Baretti, Dung Thi Le · 2018 · Pharmacology & Therapeutics
64. Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
    Rajarsi Mandal, Robert M. Samstein, Ken-Wing Lee, Jonathan J. Havel, Hao Wang, Chirag Krishna, Erich Y. Sabio, Vladimir Makarov, Fengshen Kuo, Pedro Blecua et al. · 2019 · Science
65. The foundations of immune checkpoint blockade and the ipilimumab approval decennial
    Alan J. Korman, Sarah C. Garrett-Thomson, Nils Lönberg · 2021 · Nature Reviews Drug Discovery
66. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
    Kimberley M. Heinhuis, Willeke Ros, Marleen Kok, Neeltje Steeghs, Jos H. Beijnen, Jan H.M. Schellens · 2019 · Annals of Oncology
67. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
    Sri Krishna, Frank J. Lowery, Amy R. Copeland, Erol Bahadiroglu, Ratnadeep Mukherjee, Li Jia, James Anibal, Abraham Sachs, Serifat O. Adebola, Devikala Gurusamy et al. · 2020 · Science
68. CD4 and CD8 T lymphocyte interplay in controlling tumor growth
    Dmitrij Ostroumov, Nora Fekete-Drimusz, Michael Saborowski, Florian Kühnel, Norman Woller · 2017 · Cellular and Molecular Life Sciences
69. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
    Mark M. Yarchoan, Lee A. Albacker, Alexander C. Hopkins, Meagan Montesion, Karthikeyan Murugesan, Teena Vithayathil, Neeha Zaidi, Nilofer Saba Azad, Daniel A. Laheru, Garrett Michael Frampton et al. · 2019 · JCI Insight
70. Guidelines for the use of flow cytometry and cell sorting in immunological studies *
    Andrea Cossarizza, Hyun‐Dong Chang, Andreas Radbruch, Mübeccel Akdiş, Immanuel Andrä, Francesco Annunziato, Petra Bächer, Vincenzo Barnaba, Luca Battistini, Wolfgang Michael Bauer et al. · 2017 · European Journal of Immunology
71. Identification of neoantigens for individualized therapeutic cancer vaccines
    Franziska Lang, Barbara Schrörs, Martin Löwer, Özlem Türeci, Uğur Şahin · 2022 · Nature Reviews Drug Discovery
72. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
    Topper, Michael J., Vaz, Michelle, Chiappinelli, Katherine B., DeStefano Shields, Christina E., Niknafs, Noushin, Yen, Ray-Whay Chiu, Wenzel, Alyssa, Hicks, Jessica, Ballew, Matthew, Stone, Meredith et al. · 2017 · Cell
73. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
    Hyunchul Jung, Hong Sook Kim, Jeong Yeon Kim, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Manel Esteller, Se‐Hoon Lee, Jung Kyoon Choi · 2019 · Nature Communications
74. Application of PD-1 Blockade in Cancer Immunotherapy
    Xiaomo Wu, Zhongkai Gu, Chen Yang, Borui Chen, Wei Chen, Liqiang Weng, Xiaolong Liu · 2019 · Computational and Structural Biotechnology Journal
75. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
    Luoyan Ai, Antao Xu, Jie Xu · 2020 · Advances in experimental medicine and biology
76. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
    Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok · 2018 · Cancer Cell
77. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
    Cossarizza, Andrea, Chang, Hyun‐Dong, Radbruch, Andreas, Abrignani, Sergio, Addo, Richard, Akdis, Mübeccel, Andrä, Immanuel, Andreata, Francesco, Annunziato, Francesco, Arranz, Eduardo et al. · 2021 · European Journal of Immunology
78. Targeting ALK: Precision Medicine Takes on Drug Resistance
    Jessica J. Lin, Gregory J. Riely, Alice Tsang Shaw · 2017 · Cancer Discovery
79. Roles of regulatory T cells in cancer immunity
    Yoshiko Takeuchi, Hiroyoshi Nishikawa · 2016 · International Immunology
80. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
    Patrick Alexander Ott, Elena Élez, Sandrine Hiret, Dong‐Wan Kim, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Janice M. Mehnert · 2017 · Journal of Clinical Oncology
81. Immune suppressive mechanisms in the tumor microenvironment
    David H. Munn, Vincenzo Bronte · 2015 · Current Opinion in Immunology
82. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
    D. Ross Camidge, Robert Charles Doebele, Keith M. Kerr · 2019 · Nature Reviews Clinical Oncology
83. Emerging therapies for glioblastoma: current state and future directions
    Liang Rong, Ni Li, Zhenzhen Zhang · 2022 · Journal of Experimental & Clinical Cancer Research
84. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
    Diana M. Merino, Lisa M. McShane, David A. Fabrizio, Vincent Anthony Funari, Shu‐Jen Chen, James Robert White, Paul Wenz, Jonathan F. Baden, J. Carl Barrett, Ruchi Chaudhary et al. · 2020 · Journal for ImmunoTherapy of Cancer
85. Radiotherapy combination opportunities leveraging immunity for the next oncology practice
    Fernanda Gabriela Herrera, Jean Bourhis, George Coukos · 2016 · CA A Cancer Journal for Clinicians
86. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
    Bratman, Scott V., Yang, S. Y. Cindy, Iafolla, Marco A. J., Liu, Zhihui, Hansen, Aaron R., Bedard, Philippe L., Lheureux, Stephanie, Spreafico, Anna, Razak, Albiruni Abdul, Shchegrova, Svetlana et al. · 2020 · Nature Cancer
87. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
    Patrick Alexander Ott, Yung‐Jue Bang, Dominique Berton-Rigaud, Elena Élez, Michael Jon Pishvaian, Hope S. Rugo, Igor J. Puzanov, Janice M. Mehnert, Kyaw Lwin Aung, Juanita Suzanne Lopez et al. · 2017 · Journal of Clinical Oncology
88. Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
    Kentaro Inamura · 2017 · Frontiers in Oncology
89. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
    Dongrui Wang, Xianlin Wu, Yingli Sun · 2022 · Signal Transduction and Targeted Therapy
90. Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity
    Ashley V. Kroll, Ronnie H. Fang, Yao Jiang, Jiarong Zhou, Xiaoli Wei, Chun Lai Yu, Jie Gao, Brian T. Luk, Diana Dehaini, Weiwei Gao et al. · 2017 · Advanced Materials
91. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    Gettinger, Scott, Rizvi, Naiyer A., Chow, Laura Q., Borghaei, Hossein, Brahmer, Julie, Ready, Neal, Gerber, David E., Shepherd, Frances A., Antonia, Scott, Goldman, Jonathan W. et al. · 2016 · Journal of Clinical Oncology
92. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
    Johnson, Douglas B., Frampton, Garrett M., Rioth, Matthew J., Yusko, Erik, Xu, Yaomin, Guo, Xingyi, Ennis, Riley C., Fabrizio, David, Chalmers, Zachary R., Greenbowe, Joel et al. · 2016 · Cancer Immunology Research
93. Pembrolizumab (Keytruda)
    Gin Wai Kwok, Thomas C. C. Yau, Joanne Wing Yan Chiu, Eric Tse, Yok‐Lam Kwong · 2016 · Human Vaccines & Immunotherapeutics
94. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
    Aurélie Durgeau, Yasemin Virk, Stéphanie Corgnac, Fathia Mami‐Chouaib · 2018 · Frontiers in Immunology
95. CD8+ T Cell Exhaustion in Cancer
    Joseph S. Dolina, Natalija Budimir, Graham D. Thomas, Shahram Salek‐Ardakani · 2021 · Frontiers in Immunology
96. Unravelling the biology of SCLC: implications for therapy
    Joshua K. Sabari, Benjamin H. Lok, James H. Laird, John Thomas Poirier, Charles M. Rudin · 2017 · Nature Reviews Clinical Oncology
97. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
    Michael Orth, Philipp Metzger, Sabine Gerum, Julia V. Mayerle, Günter Schneider, Claus Belka, Maximilian Schnurr, Kirsten Lauber · 2019 · Radiation Oncology
98. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
    Qingzhu Jia, Wei Wu, Yuqi Wang, Peter B. Alexander, Chengdu Sun, Zhihua Gong, Jia-Nan Cheng, Huaibo Sun, Yanfang Guan, Xuefeng Xia et al. · 2018 · Nature Communications
99. Reversing T-cell Dysfunction and Exhaustion in Cancer
    Zarour, Hassane M. · 2016 · Clinical Cancer Research
100. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity
     Charles Swanton, Nicholas McGranahan, Gabriel J. Starrett, Reuben S. Harris · 2015 · Cancer Discovery